Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. freshman Avg
|
New words:
Altacein, animal, apparent, Assessment, barrier, belong, borrowing, cap, cessation, chewing, Core, counterclaim, dumping, endpoint, extract, extractability, extraction, FSP, Gregory, hearing, hydrofluoroalkane, Incarnati, Jordan, midst, nonconvertible, PDUFA, permitted, pharmacokinetic, Philip, physical, placebo, priority, Protocol, real, Remoxy, Retrospective, safekeeping, slightly, SPA, study, toxicology, user, XRTtm
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 EX-10.1 Product Development Agreement
- 10.2 EX-10.2 Director Compensation Policy
- 31.1 EX-31.1 Section 302 Certification of the CEO
- 31.2 EX-31.2 Section 302 Certification of the CFO
- 32.1 EX-32.1 Section 906 Certification of the CEO
- 32.2 EX-32.2 Section 906 Certification of the CFO
Related press release
King Pharmaceuticals similar filings
Filing view
External links